Novo Still Has Work to Do to Build Investor Confidence, CEO Says
Novo CEO Mike Doustdar discusses investor confidence, drug testing and the potential for expanding the firm's obesity offerings. "We should also have a mindset that we don't have a patent or a monopoly on all the good ideas," Doustdar tells…
Read the full story at Bloomberg Markets ↗
ImpactNotable 40/100
Why it mattersRule-based estimate: event keywords (+6); trust 9/10.
RegionsGlobal
Published4 h ago (Tue, 22 Sep 2026 07:09:54 GMT)
RetrievedTue, 22 Sep 2026 10:00:50 GMT via rss
ClassifiedTue, 22 Sep 2026 10:00:55 GMT by heuristic